@Drug_Science blog on the new Compass #psilocybin for #depression study drugscience.org.uk/compass-phase3

From psychedelic trips to treating Treatment-Resistant Depression. The possible gamechanger COMP360

Psychiatric medicine is undergoing a seismic shift as Compass pathways announce successful results from its Phase 3 trial (COMP006).

drugscience.org.uk

A new excerpt from A World Appears: Minds Before Brains - by Michael Pollan - The Microdose themicrodose.substack.com/p/minds-befo...

Minds Before Brains

An excerpt from my new book

themicrodose.substack.com

📅Save the date! Our next Network seminar will be on "Hearing voices, suicidality, and AI-psychosis", March 20th 2026, Hybrid This is a collaboration with @hearingvoicesmic.bsky.social and #ProjectEPIC Find more info and registration here: birminghamphenomenalnetwork.blogspot.com/2025/12/netw...

Network Seminar: "Hearing voices, suicidality, and AI-psychosis", 20th March, Birmingham and Online

Location In person: Assembly Room, The Exchange, 3 Centenary Square, Birmingham, B1 2DR. Online: Teams meeting. Date and time 20th March 202...

birminghamphenomenalnetwork.blogspot.com

Great day with rich discussions. The talks all went so well together. #psychedelics #phenomenology #mentalhealth @uobphenomenal.bsky.social

And we're off to the races. Great lineup for today's @uobphenomenal.bsky.social seminar. Joined by speakers from Imperial, Exeter, Amsterdam, & Birmingham. #psychedelics #interdisciplinary #phenomenology #mentalhealth

Looking forward to the talks at our Psychedelics, Phenomenology, & Mental Health workshop as part of the Birmingham Network for Phenomenology & Mental Health. Sign up & schedule in the link.

Birmingham Network for Phenomenology and Mental Health@uobphenomenal.bsky.social · 10mo ago

Our schedule for our next network seminar has now been finalised! Check out our website for the full list of awesome talks: birminghamphenomenalnetwork.blogspot.com/2025/10/netw... P.S. there's still time to register!

🌿 Facing the end of life can bring immense distress. Could psychedelic therapy help ease the journey? drugscience.org.uk/easing-end-of-life-distress-psychedelic-uk @profjoneill.bsky.social, Laura Downey, & @profmq.bsky.social for @drugscience.bsky.social #PalliativeCare #Psychedelics #DrugScience

Easing End-of-Life Distress: Should Psychedelic Therapy Be Part of Palliative Care in the UK?

Facing a terminal diagnosis is one of life’s most difficult challenges. Beyond the physical burden of illness, patients often experience anxiety, depression, insomnia, and existential distress – a sen...

drugscience.org.uk

The Dutch Medicines Evaluation Board will host a Pipeline Meeting on 5 Nov 2025, focusing on the regulatory development of psychedelics. Pharmaceutical companies can apply to present and discuss psychedelic development challenges with Dutch regulators. Deadline: 29 Aug tinyurl.com/meb-pipeline...

Pα+ Psychedelic Bulletin #207 - Lykos Rebrands to Resilient - Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision - AbbVie-Gilgamesh Deal Viewed as Validation - Psilocybin Rescheduling Petition Heads to HHS - Much, much more... psychedelicalpha.com/news/p%ce%b1...

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation - Psychedelic Alpha

Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics •

psychedelicalpha.com

🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵 www.medrxiv.org/content/10.1...

Delighted to be part of this great new network at Birmingham, and quietly working on putting together a psychedelics and lived experience workshop as part of its activities!

Birmingham Network for Phenomenology and Mental Health@uobphenomenal.bsky.social · last yr.

👋Hi everyone! We're the Birmingham Network for Phenomenology and Mental Health - an interdisciplinary network of researchers from @unibirmingham.bsky.social working on phenomenology and mental health

Reframing Psychedelic Regulation: Tools, not Treatments In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right. The use of anesthetics as treatment tools in surgery is a useful analogy.

Come and study an MSc in 'Psychǝdǝlics: Mind, Medicine, and Culture' at Exeter – now on-campus too. Here's a lovely new video of one of our students, Nina, speaking on her experience:

Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing themicrodose.substack.com/p/texas-pass...

Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing

Plus: Oregon Psilocybin services releases its first quarterly demographic data report and Could the Czech Republic be the first EU country to approve psilocybin-assisted therapy?

themicrodose.substack.com

European Drug Report 2025: Trends and Developments now published. EUDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply and key harm reduction interventions. - www.euda.europa.eu/publications...

‪👋Hi everyone! We are an interdisciplinary group of researchers from @unibirmingham.bsky.social working on the the legal, ethical, social, and other challenges relating to the therapeutic use of psychedelics (e.g. psilocybin & MDMA). #Psychedelics #PsychedelicResearch #MedicinesRegulation

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar Matt Zorn made his name suing federal agencies over cannabis and psychedelics policy. Now, he’s inside the system as Deputy General Counsel at HHS, with a psychedelics mandate. psychedelicalpha.com/news/matt-zo...

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar - Psychedelic Alpha

Matt Zorn made his name suing federal agencies over cannabis and psychedelics policy. Now, he’s inside the system as Deputy General Counsel at HHS, with what appears to be a mandate over psychedelics…

psychedelicalpha.com

New: We take a closer look at Gilgamesh's positive Phase 2a results of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder (MDD) & speak to company execs The results should provide a welcome catalyst for the field. psychedelicalpha.com/news/gilgame...

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study - Psychedelic Alpha

As Gilgamesh Pharmaceuticals is set to share positive results from its Phase 2a study of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder later today at ASCP…

psychedelicalpha.com

The WHO has issued a rapid communication on its forthcoming guideline on controlled medicines, on which PAREA participated as an external reviewer. tinyurl.com/who-gl-rc

Interesting (critical) take on my recent New Yorker piece on psychedelics and religion. | Substack substack.com/home/post/p-...

Taking Psychedelic Spiritualities (More) Seriously

The release of a long-awaited study on psychedelics and religion ought to prompt new questions, not old cliches.

substack.com

Delighted to have welcomed participants to Birmingham last week for our roundtable on Psychedelics & Regulatory Decision-making. V interesting & fruitful discussion with a range of perspectives. #Psychedelics #PsychedelicExperience #PsychedelicResearch #PsychedelicMedicine #MedicinesRegulation

Dispatch from Breaking Convention 2025: Part 2 Inside: - Ethical dilemmas of giving psychedelics to young people - Critical role of therapist selection, - Female biology X psychedelics - Pros/cons of non-hallucinogenic psychoplastogens and more... psychedelicalpha.com/news/dispatc...

Dispatch from Breaking Convention 2025: Key Takeaways from Europe’s Largest Psychedelic Summit (Part 2) - Psychedelic Alpha

From 17–19 April, the UK’s seventh biennial psychedelic conference tackled some of the field’s most urgent questions. In this second instalment, we explore the ethical dilemmas of giving psychedelics…

psychedelicalpha.com

Participate in the Global Psychedelic Survey 2025 (GPS 2025), a large global study on psychedelic use. Sponsored by Uni of Michigan, closes May 16! Win 1 of 15 $100 Amazon gift cards. Take part: bit.ly/GPS2025-survey #GPS2025 #PsychedelicResearch #GlobalSurvey